PharmaCyte Biotech, Inc. (PMCB) is an innovative biotechnology company that leverages its proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box® to develop targeted treatments for cancers and diabetes. Incorporated in 1996, and listed on the OTCQB market under the ticker symbol "PMCB," the company is based in Laguna Hills, California.
A crucial component of PharmaCyte's promising technology is its unique approach to therapy, which involves enclosing live cells in a protective capsule and then implanting them in the body. These enclosed cells secrete proteins or other therapeutic substances precisely where they are needed, which reduces the potential for undesirable side effects and improves treatment efficacy.
The company's primary focus is developing therapies for cancer and diabetes. PharmaCyte is currently conducting clinical trials of their Cell-in-a-Box® technology combined with low-dose chemotherapy for inoperable pancreatic cancer in the USA. They also have preclinical stage programs for other types of solid cancerous tumors.
The Cell-in-a-Box® approach aims to use genetically engineered human cells to convert an inactive chemotherapy drug into its active form in the proximity of the tumor. This way, the drug affects the tumor directly while limiting the harmful effects on the patient's other healthy cells - an innovative and more individualized approach to cancer treatment.
Outside of cancer treatment, PharmaCyte also explores the potential of its technology in addressing Type 1 and insulin-dependent Type 2 diabetes. It aims to encapsulate a human liver cell line that has been genetically engineered to produce, store, and release insulin in response to the levels of blood sugar in the human body, essentially gifting the ability to control blood sugar autonomously.
The promising potential of the company's technology has attracted a team of high-profile advisers and collaborators with significant expertise in cell biology, biochemistry, and molecular biology, thereby bolstering the company's scientific prowess.
PharmaCyte Biotech, Inc. is emerging as a front-runner in the field of targeted biotherapies. With its cutting-edge technology and focus on serious diseases lacking effective treatments, the company holds significant potential for future advancements in modern medicine.